Cover Image

The Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1) Expression in Patients With Prostate Cancer: A Systematic Review and Meta-Analysis

Background: Programmed cell death ligand 1 (PD-L1) expression has been shown to correlate with poor prognosis in diverse human cancers. However, limited data exist on the prognostic and clinicopathologic significance of PD-L1 expression in prostate cancers (PCa), and the curative effect of anti-PD-1...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yan Li (Author), Qingying Huang (Author), Yaoyao Zhou (Author), Meizhi He (Author), Jianhong Chen (Author), Yubo Gao (Author), Xue Wang (Author)
Format:	Book
Published:	Frontiers Media S.A., 2019-01-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The Prognostic and Clinicopathological Roles of PD-L1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis
by: Yan Li, et al.
Published: (2019)

Prognostic and Clinicopathological Significance of PD-L1 in Patients With Bladder Cancer: A Meta-Analysis
by: Lei Zhu, et al.
Published: (2019)

Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas
by: Opal L. Reddy, et al.
Published: (2017)

Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer
by: Maureen L. Drakes, et al.
Published: (2018)

Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1), CD8+ Tumor-Infiltrating Lymphocytes and p53 in Non-Small Cell Lung Cancer: An Immunohistochemical Study
by: Hayam E. RASHED, et al.
Published: (2017)

Programmed Death Ligand 1 (PD-L1) Expression in Malignant Mesenchymal Tumors
by: Kemal KÖSEMEHMETOĞLU, et al.
Published: (2017)

Prognostic effect of programmed death-ligand 1 (PD-L1) in ovarian cancer: a systematic review, meta-analysis and bioinformatics study
by: Lin Wang
Published: (2019)

Programmed death-ligand 1 expression and its correlation with clinicopathological parameters in gallbladder cancer
by: Ji Hye Kim, et al.
Published: (2020)

The Prognostic Value of Gastric Immune Prognostic Index in Gastric Cancer Patients Treated With PD-1/PD-L1 Inhibitors
by: Li Chen, et al.
Published: (2022)

PD-L1 and PD-1 expression are correlated with distinctive clinicopathological features in papillary thyroid carcinoma
by: Yanhua Bai, et al.
Published: (2017)

Prognostic and clinicopathological significance of survivin in gynecological cancer
by: Agapiti H. Chuwa, et al.
Published: (2024)

Prognostic significance of PD-L1 expression and CD8+ T cell infiltration in pulmonary neuroendocrine tumors
by: Haiyue Wang, et al.
Published: (2018)

The Clinicopathological and Prognostic Significance of the Gross Classification of Hepatocellular Carcinoma
by: Yangkyu Lee, et al.
Published: (2018)

Prognostic significance of the programmed death ligand 1 expression in clear cell renal cell carcinoma and correlation with the tumor microenvironment and hypoxia-inducible factor expression
by: Hayriye Tatli Dogan, et al.
Published: (2018)

Relationship Between PD-L1, PD-1, CD8 and Clinicopathological Factors in Primary SCCs
by: Preslav Vasilev, et al.
Published: (2024)

Epithelioid granulomatous lesions express abundant programmed death ligand-1 (PD-L1): a discussion of adverse events in anti-PD-1 antibody-based cancer immunotherapy
by: Terufumi Kubo, et al.
Published: (2021)

PD-1 gene polymorphisms and thyroid expression of PD-1 ligands differ between Graves' and Hashimoto's diseases
by: Mayumi Kawabata, et al.
Published: (2021)

PD-L1 expression and the prognostic significance in gastric cancer: a retrospective comparison of three PD-L1 antibody clones (SP142, 28-8 and E1L3N)
by: Jing Ma, et al.
Published: (2018)

The selection of immune checkpoint inhibitors of programmed cell death (anti-PD-1) and its ligand (anti-PD-L1) makes matters more challenges for clinical practice
by: Peng-Hui Wang, et al.
Published: (2024)

Evaluation of an online training tool for scoring programmed cell death ligand-1 (PD-L1) diagnostic tests for lung cancer
by: Bharat Jasani, et al.
Published: (2020)

PD-1/PD-L1 Based Combinational Cancer Therapy: Icing on the Cake
by: Jian-ye Zhang, et al.
Published: (2020)

Prognostic value of programmed cell death ligand-1 expression in ovarian cancer: an updated meta-analysis
by: Jinlan Piao, et al.
Published: (2020)

Interaction of telmisartan and related sartans with the programmed cell death-ligand 1 (PD-L1) protein dimer: a molecular docking analysis
by: Gérard Vergoten, et al.
Published: (2023)

Programmed death-ligand 1 expression and tumor-infiltrating lymphocytes in non-small cell lung cancer: association with clinicopathologic parameters
by: Gaurav Garg, et al.
Published: (2021)

Clinicopathological and Prognostic Significance of the EML4-ALK Translocation and IGFR1, TTF1, Napsin A Expression in Patients with Lung Adenocarcinoma
by: Pınar BULUTAY, et al.
Published: (2021)

Bioinformatics analysis of the clinicopathological and prognostic significance of BAG3 mRNA in gynecological cancers
by: Zi-mo Wang, et al.
Published: (2023)

The bioinformatics analysis of the clinicopathological and prognostic significances of REG4 mRNA in gynecological cancers
by: Cong-yu Zhang, et al.
Published: (2023)

PD-1/PD-L1 Inhibitors in Cervical Cancer
by: Yuncong Liu, et al.
Published: (2019)

Expression of immune checkpoint regulators, programmed death-ligand 1 (PD-L1/PD-1), cytotoxic T lymphocyte antigen 4 (CTLA-4), and indolaimine-2, 3-deoxygenase (IDO) in uterine mesenchymal tumors
by: Alireza Samiei, et al.
Published: (2022)

The Prognostic and Therapeutic Value of PD-L1 in Glioma
by: Ruo Qiao Chen, et al.
Published: (2019)

A comparative study to assess the increased expression of programmed cell death-1 (PD1) and programmed cell death- ligand-1 (PDL1) in oral potentially malignant disorders and oral squamous cell carcinoma
by: Sonalika Srivastava, et al.
Published: (2023)

Prognostic significance of mast cells and vascular density in prostatic adenocarcinoma
by: Bismay Das, et al.
Published: (2022)

Distribution and Expression of Programmed Death Ligand -1 (PD-L1) in Non-Small Cell Carcinomas of the Lung in a Tertiary Care Centre in South India
by: Sheba S K JACOB
Published: (2021)

Expression of programmed death-ligand 1 and programmed death-1 in patients with extramammary paget's disease
by: Hiroyuki Goto, et al.
Published: (2021)

Bioinformatic analysis of the clinicopathological and prognostic significance of oocyte-arresting BTG4 mRNA expression in gynecological cancers
by: Hua-chuan Zheng, et al.
Published: (2023)

Elevated Expression of Programmed Death-1 and Programmed Death Ligand-1 Negatively Regulates Immune Response against Cervical Cancer Cells
by: Zhifang Chen, et al.
Published: (2016)

Significant metabolic alterations in non-small cell lung cancer patients by epidermal growth factor receptor-targeted therapy and PD-1/PD-L1 immunotherapy
by: Chen Yan, et al.
Published: (2022)

Biomarkers and prognostic factors of PD-1/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma
by: Nan Zhang, et al.
Published: (2024)

Metabolism and Interspecies Variation of IMMH-010, a Programmed Cell Death Ligand 1 Inhibitor Prodrug
by: Yuchen Wang, et al.
Published: (2021)

Human Leukocyte Antigen Class I and Programmed Death-Ligand 1 Coexpression Is an Independent Poor Prognostic Factor in Adenocarcinoma of the Lung
by: Yeon Bi Han, et al.
Published: (2019)